Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficiency and safety of anti-Programmed death-1
(PD-1) immunotherapy, tislelizumab, combined with EGFR-tyrosine kinase inhibitor (TKI),
afatinib as a new neoadjuvant treatment regimen for patients with resectable head and neck
squamous cell carcinoma (HNSCC).